Neuroendocrinological aspects of epilepsy: Important issues and trends in future research

Epilepsy and Behavior

Volumn 22, Issue 1, 2011, Pages 94-102

  Pack, Alison M ^a   Reddy, Doodipala Samba ^b   Duncan, Susan ^c   Herzog, Andrew ^d  

^a NewYork Presbyterian Hospital   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Bone; Epilepsy; Hormones; Neuroendocrine; Reproductive; Sex

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANDROSTANEDIOL; BENZODIAZEPINE; BICUCULLINE; CALCIUM; CARBAMAZEPINE; ESTRADIOL; ETIRACETAM; FINASTERIDE; GANAXOLONE; LAMOTRIGINE; MEDROXYPROGESTERONE ACETATE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PILOCARPINE; PROGESTERONE; TESTOSTERONE; TETRAHYDROPROGESTERONE; THYROTROPIN; THYROXINE; TOPIRAMATE; VALPROIC ACID; VITAMIN D; ZONISAMIDE;

AMENORRHEA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ANXIETY DISORDER; BONE; BONE DENSITY; BONE MASS; BONE REMODELING; CALCIUM BLOOD LEVEL; CATAMENIAL EPILEPSY; CHRONIC DISEASE; COMORBIDITY; CONTRACEPTION; DEPRESSION; DISEASE PREDISPOSITION; DRUG MEGADOSE; EMOTION; EPILEPSY; EPILEPTIC STATE; ESTROGEN BLOOD LEVEL; FEMALE INFERTILITY; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; LONGEVITY; LOW DRUG DOSE; MEDICAL RESEARCH; MENSTRUATION DISORDER; NEUROENDOCRINOLOGY; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PREGNANCY; PROGESTERONE BLOOD LEVEL; PROPHYLAXIS; REPRODUCTION; REVIEW; SECONDARY HYPERPARATHYROIDISM; SEIZURE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; STEROID THERAPY; STEROIDOGENESIS; STIGMA; STRESS; TRANQUILIZING ACTIVITY; VITAMIN SUPPLEMENTATION;

ANTICONVULSANTS; BONE DENSITY; BRAIN; EPILEPSY; FEMALE; FORECASTING; GONADAL STEROID HORMONES; HUMANS; MALE; NEUROENDOCRINOLOGY; OSTEOPOROSIS; STEROIDS;

EID: 80052482736     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.02.009     Document Type: Review

References (158)

1. Herzog A.G. Catamenial epilepsy: definition, prevalence, pathophysiology and treatment. Seizure 2008, 17:151-159.
2. Herzog A.G. Disorders of reproduction in patients with epilepsy. Seizure 2008, 17:101-110.
3. McEwen B.S. Estrogen's effects on the brain: multiple sites and molecular mechanisms [invited review]. J Appl Physiol 2001, 91:2785-2801.
4. Woolley C.S., McEwen B.S. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994, 14:7680-7687.
5. Woolley C.S., Weiland N.G., McEwen B.S., Schwartzkroin P.A. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 1997, 17:1848-1859.
6. Rudick C.N., Woolley C.S. Estrogen regulates functional inhibition of hippocampal CA1 pyramidal cells in the adult female rat. J Neurosci 2001, 21:6532-6543.
7. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J 1992, 6:2311-2322.
8. Smith S.S. Estrogen administration increases neuronal responses to excitatory amino acids as a long-term effect. Brain Res 1989, 503:354-357.
9. Kokate T.G., Svensson B.E., Rogawski M.A. Anticonvulsant activity of neurosteroids: correlation with γ-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 1994, 270:1223-1229.
10. Kokate T.G., Cohen A.L., Karp E., Rogawski M.A. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 1996, 35:1049-1056.
11. Kaminski R.M., Marini H., Kim W.-J., Rogawski M.A. Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia 2005, 46:819-827.
12. Frye C.A. The neurosteroid 3α,5α-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. Brain Res 1995, 696:113-120.
13. A receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 2005, 8:797-804.
14. A receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998, 392:926-930.
15. A-receptor currents in a rat model of chronic temporal lobe epilepsy. J Physiol 2001, 537:453-465.
16. Herzog A.G. Reproductive endocrine regulation in men with epilepsy: effects on reproductive function and neuronal excitability. Ann Neurol 2002, 51:539-542.
17. Levesque L.A., Herzog A.G., Seibel M.M. The effect of phenytoin and carbamazepine on dehydroepiandrosterone sulfate in men and women who have partial seizures with temporal lobe involvement. J Clin Endocrinol Metab 1986, 63:243-245.
18. Isojarvi J.I., Turkka J., Pakarinen A.J., et al. Thyroid function in men taking carbamazepine, oxcarbazepine or valproate for epilepsy. Epilepsia 2001, 42:930-934.
19. Herzog A.G. Epilepsy. Continuum 2009, 16:37-66.
20. Herzog A.G. Psychoneuroendocrine aspects of temporolimbic epilepsy: I. Brain, reproductive steroids and emotions. Psychosomatics 1999, 40:95-100.
21. Herzog A.G., Klein P., Ransil B.J. Three patterns of catamenial epilepsy. Epilepsia 1997, 38:1082-1088.
22. Kalinin V.V., Zheleznova E.V. Chronology and evolution of temporal lobe epilepsy and endocrine reproductive dysfunction in women: relationships to side of focus and catameniality. Epilepsy Behav 2007, 11:185.
23. Herzog A.G. Is there a lateralized asymmetry in the sensitivity of the brain to hormones in epilepsy? [editorial]. Epilepsy Behav 2007, 11:157-159.
24. Quigg M., Smithson S.D., Fowler K.M., Sursal T., Herzog A.G. Laterality and location influence catamenial seizure expression in women with partial epilepsy. Neurology 2009, 73:223-227.
25. Herzog A.G., Fowler K.M., Smithson S.D., et al. Relationship of catamenial epilepsy and level of catameniality to epilepsy laterality and focality. Epilepsia 2009, 50:41. and the Progesterone Therapy Study Group.
26. Zimmerman A.W., Holden K.R., Reiter E.O., Dekaban A.S. Medroxyprogesterone acetate in the treatment of seizures associated with menstruation. J Pediatr 1973, 83:959-963.
27. Mattson R.H., Cramer J.A., Caldwell B.V., Siconolfi B.C. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology (Cleve) 1984, 34:1255-1258.
28. Bauer J., Wildt L., Flugel D., Stefan H. The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients. J Neurol 1992, 239:284-286.
29. Haider Y., Barnett D.B. Catamenial epilepsy and goserelin. Lancet 1991, 338:1530.
30. Dana Haeri J., Richens A. Effect of norethistrone on seizures associated with menstruation. Epilepsia 1983, 24:377-381.
31. Herzog A.G. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. Neurology 1986, 36:1607-1610.
32. Herzog A.G. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 1999, 52:1917-1918.
33. Marinus Pharmaceuticals, Inc. announces positive results of its phase 2 clinical trial of ganaxolone as adjunctive therapy. Press release, March 3, 2009. http://www.marinuspharma.com/nr_positive_results.html.
34. Herzog A.G., Farina E.L., Drislane F.W., et al. A comparison of anastrozole and testosterone versus placebo and testosterone treatment of sexual dysfunction in men with epilepsy and hypogonadism. Epilepsy Behav 2010, 17:264-271.
35. Rättyä J., Turkka J., Pakarinen A.J., et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001, 56:31-36.
36. Herzog A., Drislane F., Schomer D., et al. Differential effects of anti-epileptic drugs on sexual function and hormones in men with epilepsy. Neurology 2005, 65:1016-1020.
37. Toone B.K., Edeh J., Nanjee M.N., Wheeler M. Hyposexuality and epilepsy: a community survey of hormonal and behavioural changes in male epileptics. Psychol Med 1989, 19:937-943.
38. Jensen P., Jensen S.B., Sørensen P.S., et al. Sexual dysfunction in male and female patients with epilepsy: a study of 86 outpatients. Arch Sex Behav 1990, 19:1-14.
39. Isojärvi J.I., Repo M., Pakarinen A.J., Lukkarinen O., Myllylä V.V. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia 1995, 36:366-370.
40. Murialdo G., Galimberti C.A., Fonzi S., et al. Sex hormones and pituitary function in male epileptic patients with altered or normal sexuality. Epilepsia 1995, 36:360-365.
41. Talbot J.A., Sheldrick R., Caswell H., Duncan S. Sexual function in men with epilepsy: how important is testosterone?. Neurology 2008, 70:1346-1352.
42. Duncan S., Talbot J., Sheldrick R., Caswell H. Erectile function, sexual desire and psychological well being in men with epilepsy. Epilepsy Behav 2009, 15:351-357.
43. Bear D.M., Fedio P. Quantitative analysis of interictal behavior in temporal lobe epilepsy. Arch Neurol 1977, 34:454-467.
44. Daniele A., Azzoni A., Bizzi A., et al. Sexual behavior and hemispheric laterality of the focus in patients with temporal lobe epilepsy. Biol Psychiatry 1997, 42:617-624.
45. Herzog A.G., Coleman A.E., Jacobs A.R., et al. The relationship of sexual function to the laterality of epileptiform discharges and reproductive hormone levels in women with temporolimbic epilepsy. Epilepsy Behav 2003, 4:407-413.
46. Toone B.K., Wheeler M., Nanjee M., et al. Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics. J Neurol Neurosurg Psychiatry 1983, 46:824-826.
47. Macphee G.J., Larkin J.G., Butler E., Beastall G.H., Brodie M.J. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988, 29:468-475.
48. Bancroft J. The endocrinology of sexual arousal. J Endocrinol 2005, 186:411-427.
49. Morales A., Buvat J., Gooren L. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004, 1:69-81.
50. Isidori A., Giannetta E., Gianfrilli D., et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol 2005, 63:381-394.
51. Svalheim S., Taubøll E., Bjørnenak T., et al. Do women with epilepsy have increased frequency of menstrual disturbances?. Seizure 2003, 12:529-533.
52. Dansky L.V., Andermann E., Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980, 21:261-271.
53. Schupf N., Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia 1996, 37:833-840.
54. Artama M., Isojarvi J.I., Raitanen J., et al. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004, 159:1057-1063.
55. Herzog A.G., Seibel M.M., Schomer D.L., Vaitukaitis J.L., Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986, 43:341-346.
56. Bilo L., Meo R., Valentino R., et al. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril 1991, 55:705-711.
57. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993, 329:1383-1388.
58. Betts T., Yarrow H., Dutton N., et al. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 2003, 12:323-329.
59. Morrell M.J., Hayes F.J., Sluss P.M., et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008, 64:200-211.
60. Bauer J., Jarre A., Klingmuller D., Elger C.E. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000, 41:163-167.
61. Stephen L.J., Kwan P., Shapiro D., Dominiczak M., Brodie M.J. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001, 42:1002-1006.
62. Herzog A.G., Coleman A.E., Jacobs A.R., et al. Interictal EEG discharges, reproductive hormones and menstrual disorders in epilepsy. Ann Neurol 2003, 54:625-637.
63. Mikkonen K., Vainionpaa L.K., Pakarinen A.J., et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurol 2004, 62:445-450.
64. Herzog A.G., Schachter S.C. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001, 42:311-315.
65. Von Krogh K., Harjen H., Alma C., et al. The effect of valproate and levetiracetam on steroidogenesis in forskolin-stimulated H295R cells. Epilepsia 2010, 51:2280-2288.
66. Herzog A.G. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology 1993, 43:1907-1910.
67. Harden C.L., Koppel B.S., Herzog A.G., Nikolov B.G., Hauser W.A. Seizure frequency is associated with age of menopause in women with epilepsy. Neurology 2003, 61:451.
68. Olafsson E., Hallgrimsson J.T., Hauser W.A., et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998, 39:887-892.
69. Mosher W.D., Martinez G.M., Chandra A., Abma J.C., Willson S.J. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004, 350:1-36.
70. Davis A.R., Pack A.M., Kritzer J., Yoon A., Camus A. Reproductive history, sexual behavior and use of contraception in women with epilepsy. Contraception 2008, 77:405-409.
71. Pack A.M., Davis A.E., Kritzer J., Yoon A., Camus A. Antiepileptic drugs: are women aware of interactions with oral contraceptives and potential teratogenicity?. Epilepsy Behav 2009, 14:640-644.
72. Herzog A.G., Fowler K.M., Smithson S.D., Sursal T.H. Hormonal contraception and seizures. Epilepsia 2008, 49(Suppl. 7):42. and the Progesterone Trial Group.
73. DeLeo V., Sabatino A., Musacchio M.C., et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010, 82:276-280.
74. Coulam C.B., Annegers J.F. Do anticonvulsants reduce the efficacy of oral contraceptives?. Epilepsia 1979, 20:519-526.
75. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002, 16:263-272.
76. Doose D.R., Wang S.S., Padmanabhan M., et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects with epilepsy. Epilepsia 2003, 44:540-549.
77. Sabers A., Buchholt J.M., Udall P., Hansen E.L. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001, 47:151-154.
78. Sabers A., Ohman I., Christensen J., Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003, 61:570-571.
79. Herzog A.G., Farina E.L., Blum A.S. Fluctuation in serum valproate levels with oral contraceptive use. Epilepsia 2005, 46:970-971.
80. Herzog A.G., Blum A.S., Farina E., et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009, 72:909-914.
81. Sidhu J., Job S., Singh S., Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006, 61:191-199.
82. Kennedy F., Morrow J., Hunt S., et al. Malformation risks of antiepileptic drugs in pregnancy: an update from the UP Epilepsy and Pregnancy Register. J Neurosurg Psychiatry 2010, 81:e18.
83. Harden C.L., Hopp J., Pennell P.B., et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009, 73:126-132.
84. Wiegartz P., Seidenberg M., Woodard A., Gidal B., Hermann B. Co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression. Neurology 1999, 53(5, Suppl. 2):S3-S8.
85. Kanner A.M. Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol 2008, 21:190-194.
86. Kanner A.M., Barry J.J., Gilliam F., Hermann B., Meador K.J. Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy?. Epilepsia 2010, 51:1152-1158.
87. Herzog A.G. Psychoneuroendocrine aspects of temporolimbic epilepsy: I. Brain, reproductive steroids and emotions. Parts 1, 2 & 3. Psychosomatics 1999, 40:95-116.
88. Strohle A., Romeo E., Hermann B., et al. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 1999, 45:274-277.
89. Strohle A., Pasini A., Romeo E., et al. Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatr Res 2000, 34:183-186.
90. Möhlig M., Jürgens A., Spranger J., et al. The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. Eur J Endocrinol 2006, 155:127-130.
91. Smithson S.D., Dworetzky B.A., Bromfield E.B., et al. Premenstrual dysphoric disorder in women with epilepsy: relationship to epileptic, antiepileptic drug and reproductive features. Epilepsia 2009, 50:47.
92. Pack A.M., Walczak T.S. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol 2008, 83:305-328.
93. Verrotti A., Coppola G., Parisi P., Mohn A., Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 2010, 112:1-10.
94. Mikati M.A., Dib L., Yamout B., Sawaya R., Rahi A.C. Fuleihan Gel-H. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 2006, 67:2005-2014.
95. Reddy D.S. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009, 85:1-30.
96. Reddy D.S. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol. Neuroscience 2004, 129:195-207.
97. Saalmann Y.B., Kirkcaldie M.T., Waldron S., Calford M.B. Cellular distribution of the GABA-A receptor-modulating 3α-hydroxy, 5α-reduced pregnane steroids in the adult rat brain. J Neuroendocrinol 2007, 19:272-284.
98. A receptors through two discrete transmembrane sites. Nature 2006, 444:486-489.
99. A receptor complex. J Pharmacol Exp Ther 1987, 241:346-353.
100. A receptor function and seizure susceptibility. J Neurosci 2002, 42:3795-3805.
101. Chisari M., Eisenman L.N., Covey D.F., Mennerick S., Zorumski C.F. The sticky issue of neurosteroids and GABA-A receptors. Trends Neurosci 2010, 33:299-306.
102. A receptors. Neuropharmacology 2009, 56:149-154.
103. A receptors. J Pharmacol Exp Ther 2010, 334:1031-1041.
104. A receptors containing the δ subunit. J Neurosci 2002, 22:1541-1549.
105. A receptors. Neuropharmacology 2002, 43:651-661.
106. Mihalek R.M., Banerjee P.K., Korpi E.R., Quinlan J.J., et al. Attenuated sensitivity to neuroactive steroids in γ-aminobutyrate type A receptor δ subunit knockout mice. Proc Natl Acad Sci USA 1999, 96:12905-12910.
107. A-receptor δ subunit. Epilepsia 2002, 43(Suppl. 5):3-8.
108. Reddy D.S. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010, 186:113-137.
109. Reddy D.S., Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther 2000, 295:1241-1248.
110. Biagini G., Baldelli E., Longo D., et al. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp Neurol 2006, 201:519-524.
111. Reddy D.S., Gangisetty O., Briyal S. Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Neuropharmacology 2010, 59:573-581.
112. Reddy D.S., Zeng Y.C. Effect of neurosteroid withdrawal on spontaneous recurrent seizures in a rat model of catamenial epilepsy [abstract]. FASEB J 2007, 21. 885.14.
113. Lawrence C., Martin B.S., Sun C., Williamson J., Kapur J. Endogenous neurosteroid synthesis modulates seizure frequency. Ann Neurol 2010, 67:689-693.
114. Smith S.S., Shen H., Gong Q.H., Zhou X. Neurosteroid regulation of GABA-A receptors: focus on the alpha4 and delta subunits. Pharmacol Ther 2007, 116:58-76.
115. Gangisetty O., Reddy D.S. Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway. Neuroscience 2010, 170:865-880.
116. Reddy D.S., Kim H.Y., Rogawski M.A. Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 2001, 42:328-336.
117. Herzog A.G., Frye C.A. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003, 53:390-391.
118. Reddy D.S., Rogawski M.A. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000, 294:909-915.
119. Reddy D.S., Rogawski M.A. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001, 42:303-310.
120. Reddy D.S., Rogawski M.A. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009, 6:392-401.
121. Reddy D.S., Woodward R. Ganaxolone: a prospective overview. Drugs Future 2004, 29:227-242.
122. Reddy D.S., Rogawski M.A. Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res 2010, 89:254-260.
123. Pack A.M. Implications of hormonal and neuroendocrine changes associated with seizures and antiepileptic drugs: a clinical perspective. Epilepsia 2010, 51(Suppl. 3):150-153.
124. Petty S.J., Hill K.D., Haber N.E., et al. Balance impairment in chronic antiepileptic drug users: a twin and sibling study. Epilepsia 2010, 51:280-288.
125. Cooper C. Epidemiology of osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2003, 307-313. Lippincott Williams &Wilkins, New York. M.J. Favus (Ed.).
126. Marcus R. Secondary forms of osteoporosis 1992, Raven Press, New York.
127. Andress D.L., Ozuna J., Tirschwell D., et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002, 59:781-786.
128. Chung S., Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994, 16:382-385.
129. Farhat G., Yamout B., Mikati M.A., Demirjian S., Sawaya R., El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002, 58:1348-1353.
130. Sheth R.D., Wesolowski C.A., Jacob J.C., et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995, 127:256-262.
131. Tsukahara H., Kimura K., Todoroki Y., et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002, 44:247-253.
132. Valimaki M.J., Tiihonen M., Laitinen K., et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994, 9:631-637.
133. Verrotti A., Greco R., Morgese G., Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000, 47:385-388.
134. Verrotti A., Greco R., Latini G., Morgese G., Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002, 43:1488-1492.
135. Dent C.E., Richens A., Rowe D.J., Stamp T.C. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 1970, 4:69-72.
136. Kruse R. Osteopathies in antiepileptic long-term therapy (preliminary report). Monatsschr Kinderheilkd 1968, 116:378-381.
137. Richens A., Rowe D. Calcium metabolism in patients with epilepsy. Br Med J 1970, 4:803-804.
138. Mosekilde L., Melsen F. Dynamic differences in trabecular bone remodeling between patients after jejunoileal bypass for obesity and epileptic patients receiving anticonvulsant therapy. Metab Bone Dis Relat Res 1980, 2:77-82.
139. Weinstein R.S., Bryce G.F., Sappington L.J., King D.W., Gallagher B.B. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984, 58:1003-1009.
140. Vestergaard P. Epilepsy, osteoporosis and fracture risk: a meta-analysis. Acta Neurol Scand 2005, 112:277-286.
141. Nissen-Meyer L.S., Svalheim S., et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007, 48:1850-1860.
142. Pack A.M., Morrell M.J., Marcus R., et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005, 57:252-257.
143. Pack A.M., Morrell M.J., Randall A., McMahon D.J., Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008, 70:1586-1593.
144. Sowers M., Crutchfield M., Bandekar R., et al. Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Miner Res 1998, 13:1134-1140.
145. Ensrud K.E., Walczak T.S., Blackwell T., Ensrud E.R., Bowman P.J., Stone K.L. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004, 62:2051-2057.
146. Stephen L.J., McLellan A.R., Harrison J.H., et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999, 8:339-342.
147. Valimaki M.J., Tiihonen M., Laitinen K., et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994, 9:631-637.
148. Tjellesen J., Nilas L., Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients?. Acta Neurol Scand 1983, 68:13-19.
149. Bramswig S., Zitterman A., Berthold H.K. Carbamzepine does not alter biochemical parameters of bone turnover in healthy male adults. Calcif Tissue Int 2003, 73:356-360.
150. Nakade O., Baylink D.J., Lau K.H. Phenytoin at micromolar concentrations is an osteogenic agent for human-mandible-derived bone cells in vitro. J Dent Res 1995, 74:331-337.
151. Takahashi A., Onodera K., Shinoda H., et al. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 2000, 82:82-84.
152. Hahn T.J., Scharp C.R., Richardson C.A., et al. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978, 62:406-414.
153. Feldkamp J., Becker A., Witte O.W., et al. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000, 108:37-43.
154. Von Burstel Smith M., Crofoot K., Rodriguez-Proteau R., et al. Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. Toxicol In Vitro 2007, 21:855-862.
155. Auszmann J.M., Vernillo A.T., Fine A.S., et al. The effect of phenytoin on parathyroid hormone simulated cAMP activity in cultured murine osteoblasts. Life Sci 1990, 46:351-357.
156. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010, 95:3569-3577.
157. Pack A.M., Morrell M.J., Randall A., McMahon D.J., Shane E. Antiepileptic drugs affect bone loss via reproductive hormones. Proceedings, American Society of Bone and Mineral Metabolism [abstract] 2007.
158. Food and Nutrition Board Dietary reference intakes for calcium and vitamin D [consensus report] Released: 30 November 2010. Available at:. http://www.iom.edu/Reports/2010/Dietary-reference-intakes-for-calcium-and-vitamin-D.aspx.